Our annual conference is designed to provide a place for bio-life scientists and executives interested in developing and establishing global networks and partnerships that can grow into powerful cross-border collaborations.
Potomac, MD (PRWEB) May 23, 2010
The Chinese Biopharmaceutical Association-USA (CBA) announced today that it is holding its 15th Annual Conference June 12 -13 in Maryland, US.
The event will highlight current breakthroughs, new opportunities and future challenges in biopharmaceutical development. It will also develop a platform for communication and collaboration among biopharmaceutical companies, CROs, research institutions and government agencies, as well as individual research scientists, biopharmaceutical executives, entrepreneurs and venture capitalists.
With an anticipated attendance of more than 500, the conference offers a unique opportunity for those interested in fostering collaborations.
“The goal of our annual conference is to provide a place for bio-life scientists and executives interested in developing and establishing global networks and partnerships to meet, share needs and opportunities and develop relationships that can grow into powerful collaborations across the border,” said Sujuan Ba, Ph.D., chairperson of the conference and President-elect of the Chinese Biopharmaceutical Association – USA. “Many partnerships have been built on the base of the relationships made from the networking and discussions during our past conferences.”
More than 30 distinguished speakers will be present, including keynote speakers Dr. Eric Green, Director, National Human Genome Research Institute, National Institutes of Health; Mr. Gabriel Leung, President, Pharmaceuticals Business, OSI Pharmaceuticals; Dr. Lynda Chin, Dana-Farber Cancer Institute, Harvard Medical School; Dr. Jonathan Yingling, Vice President of Cancer Research, Eli Lilly; and Dr. Herren Wu, Vice President, Global Head of Technology and Lead Generation of MedImmune.
During the conference, CBA will announce and present its annual CBA Brilliant Achievement Award, established in 1994 to honor outstanding individuals who have made seminal contributions to science, technology or business development in the biopharmaceutical fields. The recipient must also have moved medicine in new directions and have been actively involved in building collaborative efforts internationally to advance medical fields.
The award aims to promote public awareness of the importance of collaborations between basic and applied researchers, between academia and industry, and between researchers and entrepreneurs.
The theme of this year’s conference is Biopharmaceutical Medicines: Development and Commercialization without Borders. The conference program includes:
- An insider’s view of the current state of biopharmaceutical development and commercialization
- An emerging center for biopharmaceutical R&D – showcasing China’s biotech parks and partnering opportunities
- Novel therapeutics and companion diagnostics
- Regulatory landscape for biosimilars
- Stem cells: from metabolic syndrome to cancer
- Pathways to success in China – a bird’s-eye view through case studies
For more information or to register for the conference, please visit http://www.cba-usa.org or e-mail event(at)cba-usa(dot)org. Attendance is limited and media is highly encouraged to attend.
About the Chinese Biopharmaceutical Association - USA
The Chinese Biopharmaceutical Association – USA (CBA) is one of the largest Chinese American professional associations in the United States. Founded in 1995, CBA is an independent, non-political, not for-profit professional organization dedicated to promoting science, technology, and business development in the biopharmaceutical fields by fostering research and business collaborations around the world. The Association is led by its elected board of directors and executive committee. For more information about the CBA and its programs, visit http://www.cba-usa.org.